Virtus ETF Advisers’s Avadel Pharmaceuticals AVDL Stock Holding History

Virtus ETF Advisers’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,385	Closed	-$353K	–	502
2025 Q4	$353K	Hold	16,385	–	–	0.17%	150
2025 Q3	$250K	Hold	16,385	–	–	0.14%	189
2025 Q2	$145K	Buy	+16,385	New	+$144K	0.09%	242

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Virtus ETF Advisers's AVDL Position: Q1 2026 in Review

Virtus ETF Advisers sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 16,385 shares — an estimated $353K sold.

Virtus ETF Advisers first reported a position in AVDL in Q2 2025 and held it in 3 quarters. The position peaked at $353K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Virtus ETF Advisers reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Virtus ETF Advisers sold 16,385 Avadel Pharmaceuticals shares in Q1 2026, an estimated $353K.
Virtus ETF Advisers first reported a position in Avadel Pharmaceuticals in Q2 2025 and held it in 3 quarters.
Virtus ETF Advisers's Avadel Pharmaceuticals position peaked at $353K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Virtus ETF Advisers's 13F filing for Q1 2026, filed 14 May 2026.